$BFNH
BIOFORCE NANOSCIENCES HOLDINGS, INC.

2024 Q2 Form 10-Q Financial Statement

#000109181824000049 Filed on May 03, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $114.4K $130.8K $114.4K
YoY Change 0.45% 0.62% -0.29%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $114.4K $130.8K $114.4K
YoY Change 0.45% 0.62% -0.29%
Operating Profit -$114.4K -$130.8K -$114.4K
YoY Change 0.45% 0.62% -0.29%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $17.58K
YoY Change -23.57%
Pretax Income -$114.4K -$130.8K -$114.4K
YoY Change 0.45% 0.62% -0.29%
Income Tax
% Of Pretax Income
Net Earnings -$114.4K -$130.8K -$114.4K
YoY Change 0.45% 0.62% -0.29%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 29.27M shares 29.27M shares 29.27M shares
Diluted Shares Outstanding 29.27M shares 29.27M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $670.00 $640.00 $640.00
YoY Change 3.08% -7.25% -12.33%
Cash & Equivalents $667.00 $640.00 $638.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $667.00 $640.00 $638.00
YoY Change 1.99% -6.71% -13.08%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $667.00 $640.00 $638.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $667.00 $640.00 $638.00
YoY Change 1.99% -6.71% -13.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.430K $10.13K $2.650K
YoY Change 376.32% 533.13% 562.5%
Accrued Expenses $1.808M $1.702M $1.597M
YoY Change 30.54% 33.07% 36.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.065M $1.951M $1.820M
YoY Change 29.73% 31.98% 35.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.065M $1.951M $1.820M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.065M $1.951M $1.820M
YoY Change 29.73% 31.98% 35.0%
SHAREHOLDERS EQUITY
Retained Earnings -$160.9M -$160.8M -$160.6M
YoY Change 0.3% 0.29% 0.29%
Common Stock $158.8M $158.8M $158.8M
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.064M -$1.950M -$1.819M
YoY Change
Total Liabilities & Shareholders Equity $667.00 $640.00 $638.00
YoY Change 1.99% -6.71% -13.08%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$114.4K -$130.8K -$114.4K
YoY Change 0.45% 0.62% -0.29%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$13.39K -$17.58K -$7.080K
YoY Change 54.8% -23.74% -24.92%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.42K $17.58K 7.040K
YoY Change 55.87% -23.57% -25.27%
NET CHANGE
Cash From Operating Activities -13.39K -$17.58K -7.080K
Cash From Investing Activities 0.000
Cash From Financing Activities 13.42K $17.58K 7.040K
Net Change In Cash 30.00 $2.00 -40.00
YoY Change -175.0% -104.17% 300.0%
FREE CASH FLOW
Cash From Operating Activities -$13.39K -$17.58K -$7.080K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2024Q1 us-gaap Gross Profit
GrossProfit
usd
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Gross Profit
GrossProfit
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2024Q1 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
105750 usd
CY2023Q1 us-gaap Compensation Expense Excluding Cost Of Good And Service Sold
CompensationExpenseExcludingCostOfGoodAndServiceSold
105750 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25063 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24255 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
130813 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
130005 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-130813 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-130005 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29271755 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29271755 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29271755 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29271755 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-130813 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-130005 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7482 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1201 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
105750 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
105750 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17581 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23054 usd
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
17583 usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
23006 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17583 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23006 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-48 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
638 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
734 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
640 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
686 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1347277 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-130005 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1477282 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1819230 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-130813 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1950043 usd
CY2020Q2 bfnh Business Acquisition Equity Interests Purchased Number Of Shares
BusinessAcquisitionEquityInterestsPurchasedNumberOfShares
100000 shares
CY2020Q2 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1000 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zPKqxtWfMFz1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_866_zIM2tKRWtTJi">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024Q1 us-gaap Other Expenses
OtherExpenses
17583 usd
CY2023Q1 us-gaap Other Expenses
OtherExpenses
23006 usd
CY2024Q1 bfnh Due To Related Parties
DueToRelatedParties
238285 usd
CY2023Q1 bfnh Due To Related Parties
DueToRelatedParties
197102 usd
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000 shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
Preferred stock can be converted into 100 shares of common stock, have dividend rights at 100 times common and have voting rights equal to 100 shares of common stock
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
5 to 1 reverse split.
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29271755 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29271755 shares

Files In Submission

Name View Source Status
0001091818-24-000049-index-headers.html Edgar Link pending
0001091818-24-000049-index.html Edgar Link pending
0001091818-24-000049.txt Edgar Link pending
0001091818-24-000049-xbrl.zip Edgar Link pending
bfnh-20240331.xsd Edgar Link pending
bfnh20240331_10q.htm Edgar Link pending
bfnhlogo2019001.jpg Edgar Link pending
bfnh-20240331_cal.xml Edgar Link unprocessable
bfnh-20240331_def.xml Edgar Link unprocessable
bfnh-20240331_lab.xml Edgar Link unprocessable
bfnh-20240331_pre.xml Edgar Link unprocessable
bfnh20240331_10q_htm.xml Edgar Link completed
ex311.htm Edgar Link pending
ex312.htm Edgar Link pending
ex321.htm Edgar Link pending
ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable